Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc EBT Margin for the year ending December 31, 2023: -574.96%

Avadel Pharmaceuticals plc EBT Margin is -574.96% for the year ending December 31, 2023. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Avadel Pharmaceuticals plc EBT Margin for the year ending December 31, 2020 was -22.75%, a 65.08% change year over year.
Avadel Pharmaceuticals plc EBT Margin for the year ending December 31, 2019 was -65.16%, a 40.56% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years